{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:05:43Z","timestamp":1793037943514,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Staging inaccuracies in muscle-invasive bladder cancer (MIBC) can lead to undertreatment or overtreatment. We evaluated clinical and pathological predictors of pathologic upstaging (pUS) stratifying by neoadjuvant chemotherapy (NAC) receipt among patients undergoing robot-assisted radical cystectomy (RARC). Methods: We included patients with MIBC (\u2265cT2N0M0) who underwent RARC from February 2004 through October 2020. Patients were grouped as (1) pUS with NAC, (2) pUS without NAC, and (3) no pUS (reference). Baseline characteristics were summarized using descriptive statistics. Logistic regression assessed the association between baseline characteristics and odds for upstaging. Kaplan\u2013Meier method estimated overall survival (OS) and recurrence-free survival (RFS), and log-rank test compared the survival distribution between groups. Univariable and multivariable Cox regression models identified variables associated with OS and RFS. Results: Among 277 patients, 38.6% (n = 107) were upstaged with NAC (n = 37) or without NAC (n = 70). Most were male (79%), white (72%), and had cT2 stage (85%). Median age at surgery was 72 yrs. Preoperative hydronephrosis showed higher odds of upstaging [OR 2.24 (95% CI, 1.31\u20133.81), p = 0.003]. pUS with NAC [HR 1.99 (95% CI, 1.23\u20133.22), p = 0.005] and without NAC [HR 3.18 (95% CI, 2.21\u20134.55), p &lt; 0.001] predicted worse OS (33.5 vs. 18.8 mos) compared to patients without pUS (135.3 mos). pUS with NAC [HR 2.49 (95% CI, 1.58\u20133.94) p &lt; 0.001] and without NAC [HR 3.02 (95% CI 2.11\u20134.31), p &lt; 0.001] predicted worse RFS. Conclusions: Preoperative hydronephrosis was the strongest predictor for pUS, independent of other baseline covariates. This highlights the need for better pre-operative risk stratification strategies for patients with MIBC undergoing RARC.<\/jats:p>","DOI":"10.3390\/cancers17193265","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:41:02Z","timestamp":1760002862000},"page":"3265","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4334-1300","authenticated-orcid":false,"given":"Salvador","family":"Jaime-Casas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Yip","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lama","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-6496","authenticated-orcid":false,"given":"Vitor","family":"Goes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":false,"given":"Miguel","family":"Zugman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koral","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Barragan-Carrillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-7356","authenticated-orcid":false,"given":"Hedyeh","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-9821","authenticated-orcid":false,"given":"Daniela V.","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-9514","authenticated-orcid":false,"given":"Benjamin","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton S.","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1344","authenticated-orcid":false,"given":"Kevin G.","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram E.","family":"Yuh","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-4527","authenticated-orcid":false,"given":"Alexander","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_2","unstructured":"World Bladder Cancer Patient Coalition (2024). GLOBOCAN 2022: Bladder Cancer 9th Most Common Worldwide, World Bladder Cancer Patient Coalition."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant Chemotherapy Plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"507","article-title":"Bladder Cancer: Diagnosis and Treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dobruch, J., and Oszczud\u0142owski, M. (2021). Bladder Cancer: Current Challenges and Future Directions. Medicina, 57.","DOI":"10.3390\/medicina57080749"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","article-title":"Multimodal management of muscle-invasive bladder cancer","volume":"38","author":"Park","year":"2014","journal-title":"Curr. Probl. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: A multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1748-717X-9-213","article-title":"Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival","volume":"9","author":"Lee","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yip, W., Jaime-Casas, S., Kothari, A., Sullivan, M., Ballas, L.K., Escobar, D., Schuckman, A.K., Rosenberg, J.E., and Coleman, J.A. Urothelial carcinoma: Perioperative considerations from top to bottom. CA Cancer J Clin, 2025.","DOI":"10.3322\/caac.70019"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.hoc.2021.02.006","article-title":"Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer","volume":"35","author":"Konieczkowski","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2012.11424.x","article-title":"A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer","volume":"111","author":"Mitra","year":"2013","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/UA.UA_186_20","article-title":"Factors related to upstaging of clinical stage T2 organ-confined bladder cancer following radical cystectomy: A multicenter study","volume":"14","author":"Ibrahim","year":"2022","journal-title":"Urol. Ann."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","article-title":"Upstaging of urothelial cancer at the time of radical cystectomy: Factors associated with upstaging and its effect on outcome","volume":"110","author":"Turker","year":"2012","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semradonc.2022.10.006","article-title":"The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer","volume":"33","author":"Stecca","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2006.07.009","article-title":"Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series","volume":"51","author":"Bartsch","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wong, C.H.-M., Ko, I.C.-H., Leung, D.K.-W., Kang, S.H., Kitamura, K., Horie, S., Muto, S., Ohyama, C., Hatakeyama, S., and Patel, M. (2024). Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy. Cancers, 16.","DOI":"10.3390\/cancers16162826"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil\/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG\/RTOG 0712\u2014A Randomized Phase II Trial","volume":"37","author":"Coen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.7150\/jca.28989","article-title":"A review on the accuracy of bladder cancer detection methods","volume":"10","author":"Zhu","year":"2019","journal-title":"J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wong, V.K., Ganeshan, D., Jensen, C.T., and Devine, C.E. (2021). Imaging and Management of Bladder Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061396"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of Tumor-Informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-Free Survival in Patients with Bladder Cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-Up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:50:51Z","timestamp":1760035851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193265"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193265","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}